![Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid](https://aslanpharma.com/wp-content/uploads/2018/10/ASLAN001-002SG-300x150.png)
Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid
ACT Genomics SG - ACT Genomics is proud to be selected for abstract poster presentation in ESMO 2018 Congress which starting from today till 23 October at Munich, Germany. In one of
![swallowsgroup on X: "So proud to have our poster on display today at ESMO Conference Head & Neck cancer 1110P come and take a look interesting stats #ESMO18 https://t.co/hUijMmaaed" / X swallowsgroup on X: "So proud to have our poster on display today at ESMO Conference Head & Neck cancer 1110P come and take a look interesting stats #ESMO18 https://t.co/hUijMmaaed" / X](https://pbs.twimg.com/media/DqA3DX2XcAARPSv.jpg:large)
swallowsgroup on X: "So proud to have our poster on display today at ESMO Conference Head & Neck cancer 1110P come and take a look interesting stats #ESMO18 https://t.co/hUijMmaaed" / X
![Poster presented at ESMO 2018 Congress: 1043TiP - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML) - ASLAN Pharmaceuticals Poster presented at ESMO 2018 Congress: 1043TiP - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML) - ASLAN Pharmaceuticals](https://aslanpharma.com/uat/wp-content/uploads/2018/10/1043TiP-300x184.png)